Marotta, Paul

Publishing since 2003 (Junior)

Has published 22 publications in 7 years

Number of publications published per year by Marotta, Paul. (Source : PubMed)

Distribution of publications types for Marotta, Paul. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

Chan G, Taqi A, Marotta P, Levstik M, McAlister V, Wall W, Quan D. Long-term outcomes of emergency liver transplantation for acute liver failure. Liver Transpl. 2009;15;12
Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, Marotta P, Cantarovich M, Eason JD, Wiesner RH, Ramsay MA, Garcia-Valdecasas JC, Neuberger JM, Feng S, Davis CL, Gonwa TA. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15;11
Marotta P, Hueppe D, Zehnter E, Kwo P, Jacobson I. Efficacy of chronic hepatitis C therapy in community-based trials. Clin. Gastroenterol. Hepatol. 2009;7;10
Abaalkhail F, Castonguay M, Driman DK, Parfitt J, Marotta P. Lobular capillary hemangioma of the liver. HBPD INT 2009;8;3
Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl. 2009;15;2
Adams PC, McAlister V, Chakrabarti S, Levstik M, Marotta P. Is serum hepcidin causative in hemochromatosis? Novel analysis from a liver transplant with hemochromatosis. Can. J. Gastroenterol. 2008;22;10
Cooper CL, Bailey RJ, Bain VG, Anderson F, Yoshida EM, Krajden M, Marotta P. Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can. J. Gastroenterol. 2008;22;8
Bain VG, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ, Patel K, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 2008;6;6
Watt KD, Burak KW, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM. Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can. J. Gastroenterol. 2008;22;2
Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M, McLean C, Chakrabarti S, Garcia B, Driman DK. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13;4

[ See timeline ] [ See all publications ]

h=22

means that Marotta, Paul has 22 papers cited a least 22 times - methodology

Key figures

22 pub in 7 years
3.1 publications/year
best year 2009 with 5 pub
h-index 22 with 22 pub
h-ratio : 100 %

See Timeline

Ranking

It's me !

Click here if you are
Marotta, Paul.

Most frequent Journals

Liver Transpl. (9x)
Can. J. Gastroenterol. (4x)
Transplant. Proc. (3x)
Transplantation (2x)
Clin. Gastroenterol. Hepatol. (2x)

Main affiliation

University of Western Ontario/London Health Sciences Centre, Transplant Hepatology and Gastroenterology, 339 Windermere Road, London, Ontario N6A 5A5, Canada.

Latest co-workers

Deschênes M Ghent C Khakhar A Kneteman N Levstik M Levy G Lilly L Marleau D Mason A McAlister V Peltekian K Quan D Ramsay MA Scudamore C Solano E Tchervenkov J Villamil F Wall W Watt KD Yoshida EM

Back to HepaTop

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.